News
News
- Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
04/19/2018 / 22:25 - GlobeNewswire - Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
02/17/2018 / 10:02 - GlobeNewswire - Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
02/17/2018 / 10:00 - GlobeNewswire - Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients
09/27/2017 / 07:33 - GlobeNewswire - Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients
09/27/2017 / 07:30 - GlobeNewswire - Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414
08/31/2017 / 23:15 - GlobeNewswire - Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414
12/15/2016 / 19:55 - GlobeNewswire - MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor
12/13/2016 / 07:38 - GlobeNewswire - MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor
12/13/2016 / 07:30 - GlobeNewswire - MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
12/06/2016 / 07:42 - GlobeNewswire
Real-time